<DOC>
	<DOCNO>NCT01352598</DOCNO>
	<brief_summary>This study evaluate local control rate well acute late toxicity rate stereotactic body radiotherapy ( SBRT ) treatment organ confine prostate cancer .</brief_summary>
	<brief_title>Stereotactic Body Radiotherapy Prostate Cancer</brief_title>
	<detailed_description>This single site , non-randomized , prospective , phase IV trial patient organ-confined prostate cancer . Data collect include patient demographic , pathology data , tumor stage , SBRT dose fractionation scheme , dose receive adjacent critical normal tissue , tumor recurrence data , acute late toxicity . Follow data collect patient 's standard office visit . The anticipated duration study 5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patient age &gt; = 18 year Zubrod performance status 03 T13 N0 M0 adenocarcinoma prostate Prostate volume â‰¤ 100 cc Signed studyspecific consent form Exclusion Criteria Extension local tumor involve adjacent organ seminal vesicle ( T4 ) Prostate volume &gt; 100 cc Nodal involvement Metastatic disease Prior pelvic radiotherapy except part combination therapy prostate cancer History scleroderma Patients psychiatric addictive disorder would preclude obtain informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>stereotactic radiotherapy</keyword>
</DOC>